The results showed that the Revascor treatment reduced the number of patients who developed any major heart failures from 40% to 6.7%, and those are substantial numbers. Mesoblast is located in Australia. The company also has other areas of regenerative medicine with bone regrowth and they are working on developing a product for direct injection into a diseased artery at the time of the angioplasty to increase the likelihood of long term survival of the limb. I certainly like what stem cells are doing for heart disease today. In the US we have clinical trials in place for injecting stem cells directly into the heart and results are coming in favorable there as well. BD
Cephalon (Nasdaq: CEPH) said Monday that Mesoblast (ASX: MSB, Pink Sheets: MBLTY), a company in which Cephalon holds a 20% stake, released positive phase 2 study results for heart disease treatment Revascor.
To treat heart failure, Mesoblast’s Revascor treatment uses stem-cell technology to rebuild blood vessels and heart muscles.
The phase 2 study consisted of 60 patients with heart failure, monitored over a one year period. Interim results after six months showed that an injection of Revcascor reduced the number of patients who had severe heart failures over the follow-up period from 93.3% in the control group, to 44.4% in the treated patients.